Jiangsu Hengrui Pharmaceuticals (01276): SHR-3836 Injection Obtains Drug Clinical Trial Approval Notification
Hengrui Medicine (01276) announced that recently, its subsidiary Shanghai Hengrui Medicine Co., Ltd. received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration (hereinafter referred to as "NMPA") for SHR-3836 injection, and will soon start clinical trials.
Jiangsu Hengrui Pharmaceuticals (01276) announced that its subsidiary, Shanghai Jiangsu Hengrui Pharmaceuticals Co., Ltd., recently received approval from the National Medical Products Administration for the clinical trial of SHR-3836 injection. The company will soon begin the clinical trial.
SHR-3836 injection is an innovative anti-tumor drug developed independently by the company, intended for the treatment of multiple myeloma. Currently, there are no similar drugs available on the market both domestically and internationally. As of now, the total research and development investment in the SHR-3836 injection project is about 31.7 million yuan (unaudited).
Related Articles
ETS GROUP (08031): Xiao Wen'an appointed as the company's supervisor and authorized representative.
SOUNDWILL HOLD (00878) will distribute a final dividend of HK$0.1 per share on June 18th.
LITU HOLDINGS (01008) will distribute a final dividend of 2.6 Hong Kong cents per share on June 30th.
ETS GROUP (08031): Xiao Wen'an appointed as the company's supervisor and authorized representative.
SOUNDWILL HOLD (00878) will distribute a final dividend of HK$0.1 per share on June 18th.
LITU HOLDINGS (01008) will distribute a final dividend of 2.6 Hong Kong cents per share on June 30th.
RECOMMEND
State Reform Fund And Three Major Banks Backstop Voyah As It Secures Hong Kong’s First Auto IPO This Year
20/03/2026
Hong Kong IPO Irregularities Surface As Corner Placements And Retail Losses Emerge, Haizhi Technology Implicated
20/03/2026
Gold And Silver Experience Sharp Sell‑Off As Global Rate‑Hike Expectations Intensify
20/03/2026
